AstraZeneca’s Farxiga Approval In Heart Failure A First For SGLT2 Inhibitors
Executive Summary
Farxiga, with a new indication to prevent hospitalization for heart failure in type 2 diabetes patients, is the first drug among the SGLT2 class to gain this indication outside of diabetics with renal disease.
You may also be interested in...
AZ’s Farxiga Gets FDA Priority Review For Heart Failure
AstraZeneca has got off to a strong start in 2020, with the FDA granting a fast review for its diabetes drug Farxiga in heart failure and China approving Lokelma for hyperkalemia.
Five Trials To Look Out For At The AHA Meeting
Philadelphia is due to host the American Heart Association (AHA) meeting for the first time from 16-18 November, with the conference taking place in its condensed three-day format for just the second time. Scrip takes a look at the expected highlights.
Interview: AstraZeneca ‘Is More Than Oncology’
Ruud Dobber oversees AstraZeneca’s biopharmaceuticals division, which generates some 40% of group total revenues. He tells Scrip to “Watch this space.”